#### Edgar Filing: AQUINOX PHARMACEUTICALS, INC - Form 3/A

#### AQUINOX PHARMACEUTICALS, INC

Form 3/A

August 10, 2015

### FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person \* Statement AQUINOX PHARMACEUTICALS, INC [AQXP] À BAKER BROS. ADVISORS (Month/Day/Year) LP 08/07/2015 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 667 MADISON AVENUE, 21ST 08/10/2015 (Check all applicable) **FLOOR** (Street) 6. Individual or Joint/Group \_\_X\_\_ 10% Owner Director Officer Other Filing(Check Applicable Line) (give title below) (specify below) Form filed by One Reporting Person NEW YORK. NYÂ 10065 X Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security 2. Amount of Securities 3. 4. Nature of Indirect Beneficial Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5)  $2,260^{(1)}$ Â Common Stock D Â Common Stock  $2.260^{(2)}$ D Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 $Table\ II\ -\ Derivative\ Securities\ Beneficially\ Owned\ (\textit{e.g.}, puts, calls, warrants, options, convertible\ securities)$ 

1. Title of Derivative Security 2. Date Exercisable and 3. Title and Amount of 4. 6. Nature of Indirect (Instr. 4) **Expiration Date** Securities Underlying Ownership Beneficial Ownership Conversion (Month/Day/Year) Derivative Security (Instr. 5) or Exercise Form of

#### Edgar Filing: AQUINOX PHARMACEUTICALS, INC - Form 3/A

		(Instr. 4)		Price of	Derivative
Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address	Relationships				
reporting owner name, names	Director	10% Owner	Officer	Other	
BAKER BROS. ADVISORS LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065	Â	ÂΧ	Â	Â	
Baker Bros. Advisors (GP) LLC 667 MADISION AVENUE 21ST FLOOR NEW YORK, NY 10065	Â	ÂX	Â	Â	
BAKER JULIAN 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065	Â	ÂX	Â	Â	
BAKER FELIX 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065	Â	ÂX	Â	Â	
Signatures					
Name: Scott L. Lessing Title: President /s/ S Lessing	Scott L.	L. 08/10/2015			
**Signature of Reporting Person			Date	;	
Name: Scott L. Lessing Title: President /s/ S Lessing	Scott L.		08/10/2015		
**Signature of Reporting Person			Date	;	
/s/ Julian C. Baker			08/10/2	2015	
**Signature of Reporting Person			Date	;	
/s/ Felix J. Baker			08/10/2	2015	
**Signature of Reporting Person			Date	è	

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Common shares held directly by Felix J. Baker and for which Felix J. Baker has sole beneficial ownership. These shares were received in an in kind pro rata distribution from an affiliated investment fund in January 2015 without consideration. This form 3 has been amended to reflect these shares inadvertently omitted from the previous filing.
- Common shares held directly by Julian C. Baker and for which Julian C. Baker has sole beneficial ownership. These shares were received (2) in an in kind pro rata distribution from an affiliated investment fund in January 2015 without consideration. This form 3 has been amended to reflect these shares inadvertently omitted from the previous filing.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Reporting Owners 2

### Edgar Filing: AQUINOX PHARMACEUTICALS, INC - Form 3/A

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.